Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Life Sciences, Medical Devices & Health Information Technology
2025: Top 10 U.S. Biopharma Clusters 2025
Massachusetts
*Industry: Massachusetts
BPGbio, Inc.

Organization & Developments: BPGbio

Parents

*BPGbio is using AI algorithms to accelerate and de-risk the drug discovery process.
*Focus on oncology, rare disease and dermatology.
*Interrogative Biology® platform, which gathers multi-omics data from the company’s biobank of more than 100,000 samples, then uses proprietary AI software and the Frontier supercomputer at Oak Ridge National Laboratory and its peak performance of 1.6 exaflops to generate insights to be applied in clinical trials
2023: Berg had assembled a portfolio of more than 400 U.S. and international granted and pending patents as it has worked to apply the platform to develop its pipeline of drug candidates.
2024: BPGbio and University of Oxford Enter into Strategic Collaboration Focused on Breakthrough E2-based Protein Degradation Research in Oncology and CNS Diseases
2024: BPGbio Receives FDA Rare Pediatric Disease Designation for its Potential Treatment for Primary Coenzyme Q10 Deficiency
2024: BPGbio Recognized as 2024 'BioTech AI Company of the Year' by BioTech Breakthrough Awards
2024: BPM31510IV, has received orphan drug designation for glioblastoma multiforme and pancreatic cancer.